Graziella Pellegrini is a professor at the University of Modena and Reggio Emilia, a cell therapy coordinator at the Centre for Regenerative Medicine and is co-founder and R&D Director at Holostem Terapie Avanzate S.r.l. She has master's degrees in Chemistry and Pharmaceutical Technologies and in Pharmacy from the University of Genova. Prof. Pellegrini is one of the two inventors of the technology for the culture and transplantation of limbal stem cells for the treatment of blindness due to limbal stem cell deficiency; she obtained an orphan drug designation and European registration for this therapy. She developed translational medicine protocols for treatment of third-degree burns, depigmentation and a successful clinical trial on gene therapy for epidermolysis bullosa. She is currently working on the oral mucosa and urethra for a phase I clinical trial. She has coordinated scientific teams in different cities, published with Prof. Green of Harvard and was awarded for research on the central nervous system (1988), ocular pathology (2002) and the urethra (2015); in 2017 she was awarded by ISSCR for Innovation, in 2018 she won the International Prize "Lombardia è Ricerca", International Louis Jeantet Award, International Tissue Engineering Society Career Award, and in 2020 the European Women Tech Award.
She is the author of patents, book chapters and international peer-reviewed publications and a invited speaker or chairman at over 250 major scientific meetings worldwide.
Graziella Pellegrini is a professor at the University of Modena and Reggio Emilia, a cell therapy coordinator at the Centre for Regenerative Medicine and is co-founder and R&D Director at Holostem Terapie Avanzate S.r.l. She has master's degrees in Chemistry and Pharmaceutical Technologies and in Pharmacy from the University of Genova. Prof. Pellegrini is one of the two inventors of the technology for the culture and transplantation of limbal stem cells for the treatment of blindness due to limbal stem cell deficiency; she obtained an orphan drug designation and European registration for this therapy. She developed translational medicine protocols for treatment of third-degree burns, depigmentation and a successful clinical trial on gene therapy for epidermolysis bullosa. She is currently working on the oral mucosa and urethra for a phase I clinical trial. She has coordinated scientific teams in different cities, published with Prof. Green of Harvard and was awarded for research on the central nervous system (1988), ocular pathology (2002) and the urethra (2015); in 2017 she was awarded by ISSCR for Innovation, in 2018 she won the International Prize "Lombardia è Ricerca", International Louis Jeantet Award, International Tissue Engineering Society Career Award, and in 2020 the European Women Tech Award.
She is the author of patents, book chapters and international peer-reviewed publications and a invited speaker or chairman at over 250 major scientific meetings worldwide.